A citation-based method for searching scientific literature

Jessica Turner, Tahmina Begum, Roger D Smalligan. J Investig Med High Impact Case Rep 2016
Times Cited: 9







List of co-cited articles
78 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66


SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
268
55

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
55


Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
202
44


The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
Nellowe Candelario, Jedrzej Wykretowicz. Oxf Med Case Reports 2016
20
44

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
390
44

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi,[...]. J Diabetes Investig 2015
74
33


Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Juliette Sandifer Kum-Nji, Aidar R Gosmanov, Helmut Steinberg, Samuel Dagogo-Jack. J Diabetes Complications 2017
7
42

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
33

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
33

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Gian Paolo Fadini, Benedetta Maria Bonora, Angelo Avogaro. Diabetologia 2017
105
33

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
512
33

Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.
Daisuke Yabe, Masahiro Iwasaki, Hitoshi Kuwata, Takuya Haraguchi, Yoshiyuki Hamamoto, Takeshi Kurose, Kiminobu Sumita, Hitoshi Yamazato, Shigeto Kanada, Yutaka Seino. Diabetes Obes Metab 2017
45
33

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
433
33


Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C Del Gobbo, Suodi Zhai, Yiqing Song. Diabetologia 2016
51
33

Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats.
Kaori Takayanagi, Taisuke Shimizu, Yosuke Tayama, Akira Ikari, Naohiko Anzai, Takatsugu Iwashita, Juko Asakura, Keitaro Hayashi, Tetsuya Mitarai, Hajime Hasegawa. Am J Physiol Renal Physiol 2015
14
33

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Yshai Yavin, Traci A Mansfield, Agata Ptaszynska, Kristina Johnsson, Shamik Parikh, Eva Johnsson. Diabetes Ther 2016
32
33

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzo. Am J Physiol Renal Physiol 2015
71
33

Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin.
Fernando B Bonanni, Patrick Fei, Laura L Fitzpatrick. Surg Obes Relat Dis 2016
11
22

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis.
Sanjay Kalra, Rakesh Sahay, Yashdeep Gupta. Indian J Endocrinol Metab 2015
18
22

A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy.
Peter D Farjo, Kacie M Kidd, Josephine L Reece. Diabetes Care 2016
10
22

Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney.
Biff F Palmer, Deborah J Clegg, Simeon I Taylor, Matthew R Weir. J Diabetes Complications 2016
19
22

Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases.
Bala Venkatesh, Geoff Moore, Denzil Gill, Wayne Kelly. Crit Care Resusc 2015
10
22


Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin.
Trevor Wood, Allison J Pang, Julie Hallet, Paul Greig. BMJ Case Rep 2016
9
22

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
171
22

Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
15
22

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
109
22

Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Owais Rashid, Saad Farooq, Zareen Kiran, Najmul Islam. BMJ Case Rep 2016
9
22

Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin.
Arshpreet Kaur, Stephen J Winters. Endocrinol Diabetes Metab Case Rep 2015
15
22

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.
Majken Linnemann Jensen, Frederik Persson, Gregers S Andersen, Martin Ridderstråle, John J Nolan, Bendix Carstensen, Marit E Jørgensen. Diabetes Care 2017
25
22

Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
Yiting Wang, Mehul Desai, Patrick B Ryan, Frank J DeFalco, Martijn J Schuemie, Paul E Stang, Jesse A Berlin, Zhong Yuan. Diabetes Res Clin Pract 2017
28
22

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Junichiro Adachi, Yuusuke Inaba, Chisato Maki. Intern Med 2017
12
22

Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.
Saad Ullah, Noman Khan, Hassan Zeb, Hassan Tahir. SAGE Open Med Case Rep 2016
4
50

Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
Heidi Storgaard, Jonatan I Bagger, Filip K Knop, Tina Vilsbøll, Jørgen Rungby. Basic Clin Pharmacol Toxicol 2016
27
22

Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association.
Abbas E Kitabchi, Guillermo E Umpierrez, Mary Beth Murphy, Robert A Kreisberg. Diabetes Care 2006
229
22

Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy.
Anil V Nair, Berthold Hocher, Sjoerd Verkaart, Femke van Zeeland, Thiemo Pfab, Torsten Slowinski, You-Peng Chen, Karl Peter Schlingmann, André Schaller, Sabina Gallati,[...]. Proc Natl Acad Sci U S A 2012
82
22


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
22

Effect of acute hyperinsulinemia on magnesium homeostasis in humans.
Li Hao Richie Xu, Naim M Maalouf. Diabetes Metab Res Rev 2017
10
22

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
22

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
22


Adverse Effects of GLP-1 Receptor Agonists.
Theodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisaf. Rev Diabet Stud 2014
87
22



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.